Pertuzumab

(Perjeta®)

Perjeta®

Drug updated on 11/9/2023

Dosage FormInjection (intravenous; 420 mg/14 mL)
Drug ClassHER2/neu receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease
  • Indicated for use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer
  • Indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence

Product Monograph / Prescribing Information

Document TitleYearSource
Perjeta (pertuzumab) Prescribing Information.2021Genentech Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Pathologic complete response achieved in early-stage her2-positive breast cancer after neoadjuvant therapy with trastuzumab and chemotherapy vs. trastuzumab, chemotherapy, and pertuzumab: a systematic review and meta-analysis of clinical trials.2023Cureus
Evaluation of HER-2 positive breast cancer treated with dual-targeted treatment of trastuzumab plus pertuzumab. 2023Immunopharmacology and Immunotoxicology
Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis. 2023European Journal of Cancer
Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis. 2023ESMO Open
Efficacy and safety of treatment with or without pertuzumab for HER2-positive breast cancer: A meta-analysis. 2023Medicine
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis. 2023Clinical & Translational Oncology
Axillary Downstaging and the Impact of Clinical Axillary Status on Efficacy of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta-Analysis. 2023Technology in Cancer Research and Treatment
Neoadjuvant treatment with HER2-targeted therapies in HER2-positive breast cancer: a systematic review and network meta-analysis. 2022Cancers
Clinical and pharmacoeconomic combined report: pertuzumab (Perjeta). 2022CADTH
Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials. 2022Frontiers in Oncology
Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis. 2022Frontiers in Immunology
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. 2022Breast
Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis.2021Journal of Cancer
Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. 2021Future Oncology
Systematic review and meta‑analysis of febrile neutropenia risk with TCH(P) in HER2‑positive breast cancer. 2021Breast Cancer Research and Treatment
Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis. 2021CJC Open
Efficacy and safety of anti-HER2 agents in combination with chemotherapy for metastatic HER2-positive breast cancer patient: a network meta-analysis. 2021Frontiers in Oncology
Efficacy and safety of pyrotinib versus T-DM1 in HER2+ metastatic breast cancer patients pre-treated with trastuzumab and a taxane: a Bayesian network meta-analysis. 2021Frontiers in Oncology
Prolonged Responses With Trastuzumab Emtasine Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Refractory to Trastuzumab and Pertuzumab: Systematic Review of Evidence. 2021Clinical Breast Cancer
Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment. 2021Frontiers in Oncology
The efficacy and safety of additional anti-HER2-targeting drugs in the treatment of HER2-positive advanced breast cancer: a meta-analysis. 2020Anticancer Agents in Medicinal Chemistry
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. 2020Breast Cancer Research and Treatment
Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2020Journal of Oncology
A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer. 2020Breast Cancer
Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.2019BMC Cancer
A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer. 2019Breast Cancer
Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. 2019Core Evidence
The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer.2018Cancer Treatment Reviews
Epidermal growth factor receptor blockers for the treatment of ovarian cancer (review).2018Cochrane Database of Systematic Reviews

Clinical Practice Guidelines